期刊文献+

VITROS 5600分析仪检测3项心肌损伤标志物的性能评价 被引量:3

下载PDF
导出
摘要 目的验证和评价化学发光法检测心肌损伤标志物肌钙蛋白I(cTnI)、肌红蛋白(Myo)、肌酸激酶同工酶质量(CK-MB mass)的分析性能。方法参考NCCLS发布的方法学评价系列文件,对强生VITROS 5600分析仪免疫模块化学发光法检测心肌损伤标志物3项的正确度、精密度、线性范围和参考区间进行验证与评价。结果cTnI、Myo和CK-MB mass正确度验证偏倚分别为-3.75%~4.58%、-4.10%^-1.04%和2.90%~1.63%,批内精密度分别0.89%~3.33%、0.90%~0.94%和1.10%~1.74%,天间精密度分别为1.53%~6.45%、2.2%~2.80%和1.45%~2.06%,各项目呈一次性线性关系,相关系数(r)分别为0.999 2、0.998 6和0.999 0(P<0.05);按性别分组验证各项目的参考区间,结果显示大于95%的检测值在厂家提供的生物参考区间范围内。结论强生VITROS 5600分析仪化学发光法检测3项心肌损伤标志物的主要分析性能达到了厂商声明的性能和有关的质量要求,能够满足临床需要。
出处 《检验医学与临床》 CAS 2015年第21期3256-3259,共4页 Laboratory Medicine and Clinic
  • 相关文献

参考文献9

  • 1鄢盛恺.高敏感心肌肌钙蛋白检测的临床应用[J].中华检验医学杂志,2010,33(9):809-813. 被引量:28
  • 2International Organization for Standardization. ISO 15189. Medical laboratories-Particular requirements for quality and competence [S]. Geneva: ISO, 2007.
  • 3NCCLS. EP15-A2. User demonstration of performance for precision and accuracy [S]. Wayne, PA, USA= NCCLS, 2004.
  • 4NCCLS. EPS-A2. Evaluation of precision performance of quantitative methods; approved guideline-second edition [S]. Wayne,PA, USA.. NCCLS,2004.
  • 5NCCLS. EP6-A2. Evaluation of the linearity of quantita- tive measurement procedures[S]. Wayne, PA, USA~ NC- CLS, 2003.
  • 6NCCLS. C28-A2. How to define and determine reference intervals in the clinical laboratory~approved guideline-sec- ond edition[S]. Wayne, PA, USA : NCCLS, 2000.
  • 7中华人民共和国卫生部.ws/T403-2012.临床生物化学检验常规项目分析质量指标[s].北京:中华人民共和国卫生部,2012.
  • 8杨振华,潘柏申,许俊堂.中华医学会检验学会文件心肌损伤标志物的应用准则[J].中华检验医学杂志,2002,25(3):185-189. 被引量:402
  • 9胡大一.高敏心肌肌钙蛋白在急性冠状动脉综合征中的应用中国专家共识[J].中华心血管病杂志,2012,40(10):809-812. 被引量:48

二级参考文献67

  • 1潘柏申,杨振华,吴健民.冠状动脉疾病和心力衰竭时心脏标志物临床检测应用建议[J].中华检验医学杂志,2006,29(9):774-778. 被引量:73
  • 2柯元南,陈纪林.不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南[J].中华心血管病杂志,2007,35(4):295-304. 被引量:2157
  • 3Morrow DA,Cannon CP,Jesse RL,et al.National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines:clinical characteristics and utilization of biochemical markers in acute coronary syndromes.Clin Chem,2007,53:552-574.
  • 4James S,Flodin M,Johnston N,et al.The antibody configurations of cardiac troponin I assays may determine their clinical performance.Clin Chem,2006,52:832-837.
  • 5Christenson RH,Duh SH,Apple FS,et al.Toward standardization of cardiac troponin I measurements part Ⅱ:assessing commutability of candidate reference materials and harmonization of cardiac troponin I assays.Clin Chem,2006,52:1685-1692.
  • 6Cobbaert CM,Weykanp CW,Michielsen EC,et al.Timedependent instability of cardiac troponins in human plasma spiked with NIST reference material 2921.Clin Chem,2008,54:2078-2079.
  • 7Panteghini M,Bunk DM,Christenson RH,et al.Standardization of troponin I measurements:an update.Clin Chem Lab Med,2008,46:1501-1506.
  • 8Tate JR,Bunk DM,Christenson RH,et al.Standardization of cardiac troponin I measurement:past and present.Pathology,2010,42:402-408.
  • 9Alpert JS,Thygesen K,Antman E,et al.Myocardial infarction redefined:a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction.J Am Coll Cardio1,2000,36:959-969.
  • 10Thygesen K,Alpert JS,White HD,et al.Universal definition ofmyocardial infarction.Circulation,2007,116:2634-2653.

共引文献470

同被引文献25

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部